Holen Sie sich die Stockscreener-App
113.75
5.78%
6.22
Handel nachbörslich:
113.92
0.17
+0.15%
Incyte Corp Aktie (INCY) Neueste Nachrichten
INCY Maintains by UBS -- Price Target Raised to $113 - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Why is Incyte stock surging today? - Investing.com
Incyte receives positive CHMP opinion for Opzelura in moderate atopic dermatitis - grafa.com
UBS raises Incyte stock price target to $113 on biotech recovery - Investing.com
Incyte (INCY) Receives Positive CHMP Opinion for Opzelura Approval - GuruFocus
Incyte Corporation stock hits 52-week high at 112.32 USD - Investing.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis - BioSpace
Incyte stock jumps on positive EU review for eczema cream - Investing.com
Star Therapeutics' bleeding-disorder drug VGA039 gets full Phase 1/2 data spotlight - Stock Titan
Incyte wins EU step toward first steroid-free eczema cream - Stock Titan
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte extends hematology data at EHA, shares track NASDAQ biotech peers - Ad-hoc-news.de
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options - MyChesCo
Incyte stock: Is INCY outperforming the healthcare sector? - MSN
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement By Investing.com - Investing.com Canada
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Truist raises Incyte stock price target to $105 on VWD outlook - Investing.com UK
Incyte reports tafasitamab combo benefit in Phase III FrontMIND study - MSN
Incyte Corporation’s Stock Price Soars to $103.66, Marking a Robust 5.54% Uptick - Smartkarma
Why is Incyte stock gaining today? - Investing.com
Incyte Corporation (INCY) Reaches Settlement with CMS Over Medic - GuruFocus
INCY Upgraded by BMO Capital -- Price Target Raised to $94.00 - GuruFocus
Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit - Investing.com
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules - StreetInsider
Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling - TradingView
BMO upgrades Incyte stock rating on strategic progress By Investing.com - Investing.com South Africa
Incyte Stock: Is INCY Outperforming the Healthcare Sector? - Barchart.com
Incyte (INCY) Secures Approval for Minjuvi in Japan - GuruFocus
Incyte Trial Data Support New First-Line Approach in Lymphoma - MyChesCo
Incyte StockStifel lifts price target after bile duct disease data - AD HOC NEWS
Incyte secures Japanese approval for lymphoma drug Minjuvi - grafa.com
Japan clears Incyte’s Minjuvi for relapsed DLBCL patients - Stock Titan
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Yahoo! Finance Canada
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - Yahoo Finance
Incyte Corp (INCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incyte Corp (INCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Incyte Corp (INCY) Institutional Confidence - TradingKey
Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incyte Corp (INCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incyte Corp (INCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):